Luseogliflozin

DB12214InvestigationalSmall molecule

Luseogliflozin is an SGLT2 inhibitor used to manage type 2 diabetes mellitus. A medication that increases the amount of sugar expelled the urine to lower blood sugar in patients with type 2 diabetes.

Chemical structure of Luseogliflozin
Mechanism
Curator reviewed
Formula / weight
C23H30O6S · 434.55 g/mol (avg)
Code names
TS-071 · TS-71

Resolves to

Compound
UNIIC596HWF74ZCAS898537-18-3ChEMBLCHEMBL1093423ChEBI134725PubChem11988953
Clinical / RWD
ATCA10BK07
Structure
InChIKeyWHSOLWOTCHFFBK-ZQGJOIPISA-NSMILESCCOC1=CC=C(CC2=CC([C@@H]3S[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)=C(OC)C=C2C)C=C1
Targets
P31639SLC5A2

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
635Drug interactionsStructured to mechanism, not free text
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
7ContraindicationsEach with its own population and attribute set
Sign in
4Marketed productsAcross 2 countries and 2 labellers
Sign in
1ATC codeIncluding every combination product, plus 8 drug categories
Sign in
7+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Luseogliflozin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In